Welcome to our dedicated page for Pennant Group SEC filings (Ticker: PNTG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pennant Group, Inc. filings document the public reporting of a healthcare services holding company with operating subsidiaries in home health, hospice, home care and senior living. Recent Form 8-K reports furnish quarterly and annual results, Regulation FD investor materials, material agreements and amendments tied to acquisitions and financing arrangements.
Proxy filings cover governance, board matters, executive compensation and shareholder voting items. Other material-event amendments provide acquisition-related financial statements and pro forma information, while credit agreement disclosures describe term loans, leverage and coverage covenants, restrictions on indebtedness, liens, dispositions and restricted payments, and healthcare-law-related default provisions.
Pennant Group (PNTG) director reported an equity award. On 10/15/2025, the reporting person acquired 1,900 shares of common stock at a reported price of $0. Following the transaction, the individual beneficially owns 96,799 shares, held directly.
The filing states these shares vest in three annual installments beginning October 15, 2026. This is a routine director equity grant and does not reflect an open‑market purchase.
The Pennant Group (PNTG) director Christopher R. Christensen reported an award of 1,900 shares of common stock on October 15, 2025 at $0. The shares vest in three annual installments beginning October 15, 2026.
Following the transaction, he directly owned 140,291 shares and indirectly held 623,347 shares. Indirect holdings include shares held by Hobble Creek Investments, LLC, a 2020 irrevocable trust, his spouse, and shares held by his former spouse as custodian for their minor children.
Pennant Group (PNTG) reported an insider equity grant. A company director acquired 1,900 shares of common stock on 10/15/2025 at $0, indicating an award rather than an open-market purchase. According to the footnote, these shares vest in three annual installments beginning October 15, 2026.
Following this grant, the director beneficially owns 38,350 shares, held directly.
Pennant Group (PNTG) reported an insider equity transaction by a director. On 10/15/2025, the reporting person acquired 1,900 shares of common stock at $0 per share, bringing total beneficial ownership to 224,664 shares, held directly.
The filing notes these shares vest in three annual installments beginning October 15, 2026.
Pennant Group (PNTG) reported an insider equity transaction by a director on 10/15/2025. The filing shows an acquisition of 1,900 common shares at $0, with a footnote stating these shares vest in three annual installments beginning October 15, 2026. Following the transaction, the director beneficially owns 168,865 shares directly and 2,700 shares indirectly through the Nackel Family Trust, over which the director and spouse share voting and investment power.
Pennant Group (PNTG) reported an insider transaction by a director on October 15, 2025. The director acquired 1,900 shares of common stock at a reported price of $0, bringing beneficial ownership to 31,600 shares, held directly.
The filing notes these shares vest in three annual installments beginning October 15, 2026. This appears to be a routine equity award reflecting standard director compensation practices and does not change control.
Pennant Group (PNTG) reported an insider equity grant. A director acquired 2,400 shares of common stock on 10/15/2025 (transaction code A, award at $0), with these shares vesting in three annual installments beginning October 15, 2026. Following the transaction, the director beneficially owns 51,735 shares, held directly.
Pennant Group, Inc. (PNTG) disclosed a director’s option exercise. On 10/09/2025, the director exercised a stock option to acquire 10,000 shares of common stock at $11.35 per share (Transaction Code: M), increasing direct beneficial ownership to 94,899 shares following the transaction. The option was first exercisable on 07/17/2024, has an expiration date of 07/17/2033, and a 33% portion vested in 2025.
The Pennant Group, Inc. filed an amended current report to update a previously furnished press release. This 8-K/A modifies Item 7.01 of the original October 2, 2025 filing by replacing Exhibit 99.1 with an amended press release.
The updated Exhibit 99.1 is described as an amended press release dated October 2, 2025 announcing the closing of a transaction. No other items from the original report are changed, and the company clarifies that the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, for securities law purposes.
The Pennant Group, Inc. filed an amended current report to update a previously furnished press release. This 8-K/A modifies Item 7.01 of the original October 2, 2025 filing by replacing Exhibit 99.1 with an amended press release.
The updated Exhibit 99.1 is described as an amended press release dated October 2, 2025 announcing the closing of a transaction. No other items from the original report are changed, and the company clarifies that the information in Item 7.01 and Exhibit 99.1 is furnished, not filed, for securities law purposes.
The Pennant Group, Inc. amended its previously announced purchase agreement with UnitedHealth Group and Amedisys to expand the scope of a planned acquisition of home health, hospice, and palliative care businesses. The amendment adds additional entities and assets to be acquired by Pennant’s subsidiaries, including Cornerstone Healthcare, Tensaw River Healthcare, Threemile River Healthcare, and Bashaw River Healthcare. As a result, the total purchase price has been increased from $102,484,000 to $146,531,160, reflecting the larger portfolio of operations to be acquired.